Search

Displaying results 4791 - 4800 of 5449 in total
  1. Drug

    CY-1503

    go.drugbank.com/drugs/DB17605
    Investigational

    It was investigated in cardiopulmonary bypass during surgical repair of congenital heart lesions.

  2. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  3. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    [L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  4. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]

  5. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    [L54988] It is under investigation for the treatment of multiple atopic diseases, including food allergies, asthma, and atopic dermatitis.[L54988]

  6. Drug

    CP-39,332

    go.drugbank.com/drugs/DB09193
    Experimental

    It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency.

  7. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    It can be administered orally or subcutaneously. … It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production.

  8. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  9. Drug

    Efprezimod alfa

    go.drugbank.com/drugs/DB16448
    Investigational

    CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.

  10. Drug

    Phosphoaminophosphonic Acid-Adenylate Ester

    go.drugbank.com/drugs/DB04395
    Experimental

    It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]